INDP Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 9.28%, SMA50 -11.74%, SMA200 -61.99%). The stock’s 14-day RSI is 49.38 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.67% below its high and over 35.72% above its low. Average 10-day trading volume of 125.09 thousand shares is below the 3-month average of 1.06 million, indicating normal recent market interest.

Indaptus Therapeutics, Inc. generated EPS of -$31.51 over the past year. Five-year average earnings growth is 57.27%. Wall Street analysts project EPS growth of 53.89% annually over the next five years. The latest quarter delivered EPS of -$0.23. The next quarter is forecast at -$4.36. Next year's EPS is expected at $8.95. Indaptus Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 15, 2026, missed forecasts by -87.7%. The prior quarter beat by -28.9%. Over the last six quarters, Apple has recorded several small beats. These include -7.32% in March 13, 2025.

Indaptus Therapeutics, Inc. has 1.11 million shares outstanding. The public float is 889.33 thousand shares, elevated short interest at 1.17% of float. This equals 11.44 thousand shares. The short ratio is 0.49 days. Institutional investors hold 2.94% of the float. Insiders own 37.17%. Newman Michael James holds 1.37 million shares, Anderson Glen R. has 1.19 million shares and Meckler Jeffrey A has 75.37 thousand shares. Over the past six months, insider transactions show net selling. They sold 700.00 thousand shares across 1 transactions.

Indaptus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.81. This means the shares are trading below this model’s fair value.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) closed at $2.50 USD, gaining $0.05 (2.04%) from the previous close of $2.45. The stock is currently mid-range between its 52-week high and low $0.92 and $13.40. With a market capitalization of about $4.38 million, Indaptus Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.14). Key stats such as the average daily volume over the past year has been around 1.03 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Indaptus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Junyi Dai, the company employs approximately 5 people and listed since August 04, 2015. Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections.

Indaptus Therapeutics, Inc. trades at a P/E ratio of -0.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.41 trading at moderately above to book value. The P/FCF stands at -0.26, also above market averages.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) shares are flat -0.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Indaptus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.60, suggesting 404.0% upside. Our AI forecast model points to short-term strength (33.6% over two weeks), a medium-term fall (-84.8% over three months), and a longer-term loss (-83.6% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Indaptus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 33.6%, with price expected at $3.34 by July 22, 2026, within a range of $2.42 to $4.19 3-Month Outlook: Projected fall of -84.8%, reaching $0.38 by October 06, 2026, with a range of $0.06 to $0.72. 1-Year Outlook: Projected loss of -83.6%, with price at $0.41 by July 08, 2027, within a range of $0.00 to $0.00.